LONDON (Reuters) - GlaxoSmithKline said on Wednesday that Hall Barron will end his position as chief scientific officer in August after less than five years to run a new privately owned start-up biotech company.
Tony Wood will become CSO designate and assume full accountability for Research and Development (R&D) on Aug. 1.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!